Shilpa Medicare Ltd - SHILPA MEDICARE Share Price

Sector: Pharmaceuticals | ISIN: INE790G01031
₹ 437.20 (-2.92%) icon23 Feb, 2024, 12:00:00 AM
Open
₹ 450.30
Prev. Close
₹ 450.35
Turnover(lac)
₹ 3,044.14
Day's High
₹ 454.60
Day's Low
₹ 435.00
52 Wk High
₹ 454.80
52 Wk Low
₹ 222.60
Book Value
₹ 245.94
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 3,794.98
P/E
0.00
EPS
0.74
Div. Yield
0.00

Shilpa Medicare Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 2/23/2024 12:00:00 AM

    ₹ 437.2 -13.15 -2.92
  • Open
  • ₹ 450.3
  • Prev. Close
  • ₹ 450.35
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 454.6
  • Day's Low
  • ₹ 435
  • 52 Week's High
  • ₹ 454.8
  • 52 Week's Low
  • ₹ 222.6
  • Book Value
  • ₹ 245.94
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 3,794.98
  • P/E
  • 0
  • EPS
  • 0.74
  • Divi. Yield
  • 0

Shilpa Medicare Ltd Corporate Actions

01 Feb , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Feb , 2024

12:00 AM

03 Nov , 2023

12:00 AM

03 Nov , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Sep , 2023

12:00 AM

AGM

Announcement date: 01 Sep , 2023

View Details

01 Sep , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Aug , 2023

12:00 AM

03 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

21 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Jun , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

17 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Sep , 2023

12:00 AM

BookCloser

View Details

Shilpa Medicare Ltd News and Update

Image not found
  • 1 day ago |
  • 12:06 AM

Think and Learn Pvt Ltd, the company that owns Byju's, is accused of breaking India's foreign exchange rules

Image not found
  • IIFL News Service |
  • 22 February, 2024 |
  • 12:06 AM
Image not found
  • IIFL News Service |
  • 16 February, 2024 |
  • 11:57 PM
Article Image

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Shilpa Medicare Ltd SHAREHOLDING SNAPSHOT
24 February , 2024 | 12:44 PM

PROMOTER - TOTAL50.01%

Indian: 50.01%

Foreign: 0%

NON-PROMOTER - TOTAL 49.99%

Institutions: 8.58%

Non-Institutions: 41.41%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Shilpa Medicare Ltd FINANCIALS

Shilpa Medicare Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Shilpa Medicare Ltd

  • Omprakash Inani
  • Chairman (Non-Executive)
  • Vishnukant Bhutada
  • Managing Director
  • Sharath Reddy Kalakota
  • Whole-time Director
  • Arvind Vasudeva
  • Independent Director
  • Hetal Gandhi
  • Independent Director
  • Ritu Tiwary
  • Company Sec. & Compli. Officer
  • Kamal K Sharma
  • Independent Director
  • Anita Bandyopadhyay
  • Independent Director

Summary

Shilpa Medicare Limited (formerly known as Shilpa Antibiotics Limited) was incorporated as a Private Limited Company in November 20th, 1987 and has been promoted by Vishnukant C Bhutada and his associates. Shilpa Medicare Limited (SML) is engaged in manufacturing of Active Pharmaceutical Ingredients (API), Formulation and Development service. The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. The company started commercial production in November 1989. In November 1993, Shilpa Medicare Limited was converted into a Public Limited Company. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. While SMLs underlying expertise is in the field of oncology, it also derives revenue from sale of non-oncology APIs. With key products being Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.SMLs product range includes over 44 oncology and non-oncology APIs. The Companys formulation product range consists of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SMLs wholly owned subsidiary Shilpa... Read More


Reports by Shilpa Medicare Ltd


Reports by Shilpa Medicare Ltd

Company FAQ

No Record Found